Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression

Journal of Clinical Investigation

Volumn 119, Issue 3, 2009, Pages 465-477

  Byoung, Kwon Yoo ^a   Emdad, Luni ^a   Su, Zao Zhong ^a   Villanueva, Augusto ^b   Chiang, Derek Y ^c,d   Mukhopadhyay, Nitai D ^a   Mills, Alan Scott ^a   Waxman, Samuel ^e   Fisher, Robert A ^a   Llovet, Josep M ^b,e,f   Fisher, Paul B ^a,g   Sarkar, Devanand ^a,g  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOSPITAL CLÍNIC   (Spain)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^g VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CYTOCHROME P450 2B6; DIHYDRODIOL DEHYDROGENASE; FLUOROURACIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOFECTAMINE; LYMPHOID ENHANCER FACTOR 1; TRANSCRIPTION FACTOR 7; WNT PROTEIN; CELL ADHESION MOLECULE; LEF1 PROTEIN, HUMAN; MESSENGER RNA; MTDH PROTEIN, HUMAN; RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; ASTROCYTE ELEVATED GENE 1; CANCER GRADING; CARCINOGENESIS; CELL VIABILITY; CONTROLLED STUDY; GENE EXPRESSION; GENE MUTATION; IMMUNOPEROXIDASE STAINING; LIVER CELL CARCINOMA; METASTASIS; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STABLE EXPRESSION; VASCULAR TUMOR; WESTERN BLOTTING; XENOGRAFT; ANIMAL; CANCER STAGING; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; INFLAMMATION; LIVER CELL; LIVER TUMOR; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; REFERENCE VALUE; TUMOR CELL LINE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL ADHESION MOLECULES; CELL LINE, TUMOR; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTES; HUMANS; INFLAMMATION; LIVER NEOPLASMS; LYMPHOID ENHANCER-BINDING FACTOR 1; MICE; MICE, NUDE; NEOPLASM STAGING; REFERENCE VALUES; RNA, MESSENGER; RNA, NEOPLASM; TRANSPLANTATION, HETEROLOGOUS;

EID: 65649143486     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI36460     Document Type: Article

References (79)

1. El-Serag, H.B., and Rudolph, K.L. 2007. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 132:2557-2576.
2. El-Serag, H.B., Davila, J.A., Petersen, N.J., and McGlynn, K.A. 2003. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann. Intern. Med. 139:817-823.
3. Jemal, A., et al. 2008. Cancer statistics, 2008. CA Cancer J. Clin. 58:71-96.
4. Pang, R.W., et al. 2008. Biology of hepatocellular carcinoma. Ann. Surg. Oncol. 15:962-971.
5. Fuchs, C.S., et al. 2002. A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer. 94:3186-3191.
6. Lopez, P.M., Villanueva, A., and Llovet, J.M. 2006. Systematic review: evidence-based management of hepatocellular carcinoma - an updated analysis of randomized controlled trials. Aliment Pharmacol. Ther. 23:1535-1547.
7. Yeo, W., et al. 2005. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J. Natl. Cancer Inst. 97:1532-1538.
8. Llovet, J.M., Bru, C., and Bruix, J. 1999. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin. Liver Dis. 19:329-338.
9. O'Neil, B.H., and Venook, A.P. 2007. Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy. Oncologist. 12:1425-1432.
10. Georgiades, C.S., Hong, K., and Geschwind, J.F. 2008. Radiofrequency ablation and chemoembolization for hepatocellular carcinoma. Cancer J. 14:117-122.
11. Llovet, J.M., and Bruix, J. 2003. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 37:429-442.
12. Nerenstone, S., and Friedman, M. 1987. Medical treatment of hepatocellular carcinoma. Gastroenterol. Clin. North Am. 16:603-612.
13. Leung, T.W., et al. 1999. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin. Cancer Res. 5:1676-1681.
14. Patt, Y.Z., et al. 1999. Durable clinical and pathologic response of hepatocellular carcinoma to systemic and hepatic arterial administration of platinol, recombinant interferon alpha 2B, doxorubicin, and 5-fluorouracil: a communication. Am. J. Clin. Oncol. 22:209-213.
15. Abou-Alfa, G.K., et al. 2006. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 24:4293-4300.
16. Simpson, D., and Keating, G.M. 2008. Sorafenib: in hepatocellular carcinoma. Drugs. 68:251-258.
17. Llovet, J.M., et al. 2008. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359:378-390.
18. Zhu, A.X., et al. 2006. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 24:1898-1903.
19. Llovet, J.M., and Bruix, J. 2008. Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 48:1312-1327.
20. Brechot, C., Pourcel, C., Louise, A., Rain, B., and Tiollais, P. 1980. Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma. Nature. 286:533-535.
21. Feitelson, M.A., and Duan, L.X. 1997. Hepatitis B virus X antigen in the pathogenesis of chronic infections and the development of hepatocellular carcinoma. Am. J. Pathol. 150:1141-1157.
22. Kwun, H.J., Jung, E.Y., Ahn, J.Y., Lee, M.N., and Jang, K.L. 2001. p53-dependent transcriptional repression of p21(waf1) by hepatitis C virus NS3. J. Gen. Virol. 82:2235-2241.
23. Lee, M.N., et al. 2002. Hepatitis C virus core protein represses the p21 promoter through inhibition of a TGF-beta pathway. J. Gen. Virol. 83:2145-2151.
24. Boyault, S., et al. 2007. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology. 45:42-52.
25. Mann, C.D., et al. 2007. Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur. J. Cancer. 43:979-992.
26. Teufel, A., et al. 2007. Genetics of hepatocellular carcinoma. World J. Gastroenterol. 13:2271-2282.
27. Schmidt, C.M., McKillop, I.H., Cahill, P.A., and Sitzmann, J.V. 1997. Increased MAPK expression and activity in primary human hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 236:54-58.
28. McKillop, I.H., Schmidt, C.M., Cahill, P.A., and Sitzmann, J.V. 1997. Altered expression of mitogen-activated protein kinases in a rat model of experimental hepatocellular carcinoma. Hepatology. 26:1484-1491.
29. Coutant, A., et al. 2002. PI3K-FRAP/mTOR pathway is critical for hepatocyte proliferation whereas MEK/ERK supports both proliferation and survival. Hepatology. 36:1079-1088.
30. Villanueva, A., et al. 2008. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology. 135:1972-1983.e1-e11.
31. Pikarsky, E., et al. 2004. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 431:461-466.
32. Thompson, M.D., and Monga, S.P. 2007. WNT/ beta-catenin signaling in liver health and disease. Hepatology. 45:1298-1305.
33. Clevers, H. 2006. Wnt/beta-catenin signaling in development and disease. Cell. 127:469-480.
34. Katoh, M., and Katoh, M. 2006. Cross-talk of WNT and FGF signaling pathways at GSK3beta to regulate beta-catenin and SNAIL signaling cascades. Cancer Biol. Ther. 5:1059-1064.
35. Bhanot, P., et al. 1996. A new member of the frizzled family from Drosophila functions as a Wingless receptor. Nature. 382:225-230.
36. Pinson, K.I., Brennan, J., Monkley, S., Avery, B.J., and Skarnes, W.C. 2000. An LDL-receptor-related protein mediates Wnt signalling in mice. Nature. 407:535-538.
37. Tamai, K., et al. 2000. LDL-receptor-related proteins in Wnt signal transduction. Nature. 407:530-535.
38. Nelson, W.J., and Nusse, R. 2004. Convergence of Wnt, beta-catenin, and cadherin pathways. Science. 303:1483-1487.
39. Aberle, H., Bauer, A., Stappert, J., Kispert, A., and Kemler, R. 1997. beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J. 16:3797-3804.
40. Behrens, J., et al. 1996. Functional interaction of beta-catenin with the transcription factor LEF-1. Nature. 382:638-642.
41. Townsley, F.M., Cliffe, A., and Bienz, M. 2004. Pygopus and Legless target Armadillo/beta-catenin to the nucleus to enable its transcriptional co-activator function. Nat. Cell Biol. 6:626-633.
42. Cavallo, R.A., et al. 1998. Drosophila Tcf and Groucho interact to repress Wingless signalling activity. Nature. 395:604-608.
43. Fang, M., et al. 2006. C-terminal-binding protein directly activates and represses Wnt transcriptional targets in Drosophila. EMBO J. 25:2735-2745.
44. Chiang, D.Y., et al. 2008. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res. 68:6779-6788.
45. Taniguchi, K., et al. 2002. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene. 21:4863-4871.
46. de La Coste, A., et al. 1998. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc. Natl. Acad. Sci. U. S. A. 95:8847-8851.
47. Merle, P., et al. 2004. Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology. 127:1110-1122.
48. Miyoshi, Y., et al. 1998. Activation of the betacatenin gene in primary hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res. 58:2524-2527.
49. Satoh, S., et al. 2000. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat. Genet. 24:245-250.
50. Colnot, S., et al. 2004. Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas. Proc. Natl. Acad. Sci. U. S. A. 101:17216-17221.
51. Harada, N., et al. 2004. Hepatocarcinogenesis in mice with beta-catenin and Ha-ras gene mutations. Cancer Res. 64:48-54.
52. Calvisi, D.F., Factor, V.M., Loi, R., and Thorgeirsson, S.S. 2001. Activation of beta-catenin during hepatocarcinogenesis in transgenic mouse models: relationship to phenotype and tumor grade. Cancer Res. 61:2085-2091.
53. Su, Z.Z., et al. 2002. Identification and cloning of human astrocyte genes displaying elevated expression after infection with HIV-1 or exposure to HIV-1 envelope glycoprotein by rapid subtraction hybridization, RaSH. Oncogene. 21:3592-3602.
54. Kang, D.C., et al. 2005. Cloning and characterization of HIV-1-inducible astrocyte elevated gene-1, AEG-1. Gene. 353:8-15.
55. Brown, D.M., and Ruoslahti, E. 2004. Metadherin, a cell surface protein in breast tumors that mediates lung metastasis. Cancer Cell. 5:365-374.
56. Sutherland, H.G., Lam, Y.W., Briers, S., Lamond, A.I., and Bickmore, W.A. 2004. 3D3/lyric: a novel transmembrane protein of the endoplasmic reticulum and nuclear envelope, which is also present in the nucleolus. Exp. Cell Res. 294:94-105.
57. Emdad, L., et al. 2006. Activation of the nuclear factor kappaB pathway by astrocyte elevated gene-1: implications for tumor progression and metastasis. Cancer Res. 66:1509-1516.
58. Sarkar, D., et al. 2008. Molecular basis of nuclear factor-kappaB activation by astrocyte elevated gene-1. Cancer Res. 68:1478-1484.
59. Emdad, L., et al. 2007. Astrocyte elevated gene-1: recent insights into a novel gene involved in tumor progression, metastasis and neurodegeneration. Pharmacol. Ther. 114:155-170.
60. Kikuno, N., et al. 2007. Knockdown of astrocyteelevated gene-1 inhibits prostate cancer progression through upregulation of FOXO3a activity. Oncogene. 26:7647-7655.
61. Lee, S.G., Su, Z.Z., Emdad, L., Sarkar, D., and Fisher, P.B. 2006. Astrocyte elevated gene-1 (AEG-1) is a target gene of oncogenic Ha-ras requiring phosphatidylinositol 3-kinase and c-Myc. Proc. Natl. Acad. Sci. U. S. A. 103:17390-17395.
62. Lee, S.G., et al. 2008. Astrocyte elevated gene-1 activates cell survival pathways through PI3K-Akt signaling. Oncogene. 27:1114-1121.
63. Su, Z.Z., Luo, Z.Y., Guo, L.P., Li, J.Z., and Liu, Y.L. 1988. Inhibitory effect of parvovirus H-1 on cultured human tumour cells or transformed cells. Sci. Sin. [B]. 31:69-80.
64. Longley, D.B., Harkin, D.P., and Johnston, P.G. 2003. 5-fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer. 3:330-338.
65. Hodgson, E., and Rose, R.L. 2007. The importance of cytochrome P450 2B6 in the human metabolism of environmental chemicals. Pharmacol. Ther. 113:420-428.
66. Yoshinare, K., et al. 2003. Gene expression in colorectal cancer and in vitro chemosensitivity to 5-fluorouracil: a study of 88 surgical specimens. Cancer Sci. 94:633-638.
67. Oguri, T., et al. 2005. The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells. Lung Cancer. 49:345-351.
68. Oguri, T., et al. 2007. MRP8/ABCC11 directly confers resistance to 5-fluorouracil. Mol. Cancer Ther. 6:122-127.
69. Powell, C.M., Rudge, T.L., Zhu, Q., Johnson, L.F., and Hansen, U. 2000. Inhibition of the mammalian transcription factor LSF induces S-phase-dependent apoptosis by downregulating thymidylate synthase expression. EMBO J. 19:4665-4675.
70. Agarwal, R., D'Souza, T., and Morin, P.J. 2005. Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity. Cancer Res. 65:7378-7385.
71. Gesierich, S., Berezovskiy, I., Ryschich, E., and Zoller, M. 2006. Systemic induction of the angiogenesis switch by the tetraspanin D6.1A/CO-029. Cancer Res. 66:7083-7094.
72. Nair, R.R., Solway, J., and Boyd, D.D. 2006. Expression cloning identifies transgelin (SM22) as a novel repressor of 92-kDa type IV collagenase (MMP-9) expression. J. Biol. Chem. 281:26424-26436.
73. Wajapeyee, N., Serra, R.W., Zhu, X., Mahalingam, M., and Green, M.R. 2008. Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell. 132:363-374.
74. Mazurek, S., Boschek, C.B., Hugo, F., and Eigenbrodt, E. 2005. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin. Cancer Biol. 15:300-308.
75. Ye, X., et al. 2007. Downregulation of Wnt signaling is a trigger for formation of facultative heterochromatin and onset of cell senescence in primary human cells. Mol. Cell. 27:183-196.
76. Filali, M., Cheng, N., Abbott, D., Leontiev, V., and Engelhardt, J.F. 2002. Wnt-3A/beta-catenin signaling induces transcription from the LEF-1 promoter. J. Biol. Chem. 277:33398-33410.
77. Bissell, D.M., and Guzelian, P.S. 1980. Phenotypic stability of adult rat hepatocytes in primary monolayer culture. Ann. N. Y. Acad. Sci. 349:85-98.
78. Sarkar, D., et al. 2007. Eradication of therapy-resistant human prostate tumors using a cancer terminator virus. Cancer Res. 67:5434-5442.
79. Wurmbach, E., et al. 2007. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology. 45:938-947.